Repeated rating improves value of diagnostic dopaminergic challenge tests in Parkinson's disease
Clinicians use acute challenges with levodopa (LD) and/or apomorphine (A) for diagnostic dopaminergic response tests in Parkinson's disease (PD) patients. We consecutively compared the value of both drugs with performance of repeated ratings and adverse effect recording. Oral administration of...
Gespeichert in:
| Veröffentlicht in: | Journal of Neural Transmission 2003-06, Vol.110 (6), p.603-609 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 609 |
|---|---|
| container_issue | 6 |
| container_start_page | 603 |
| container_title | Journal of Neural Transmission |
| container_volume | 110 |
| creator | MÜLLER, Th BENZ, S BÖRNKE, C RUSS, H PRZUNTEK, H |
| description | Clinicians use acute challenges with levodopa (LD) and/or apomorphine (A) for diagnostic dopaminergic response tests in Parkinson's disease (PD) patients. We consecutively compared the value of both drugs with performance of repeated ratings and adverse effect recording. Oral administration of 200 mg LD was superior to subcutaneous injection of 4 mg A in terms of tolerability and onset of temporary UPDRS motor score decline ([previously untreated PD patients] LD: 4.02 [mean] +/- 2.45 [SD] [significant decrease: p = 1.42 E-07] vs. A: 1.58 +/- 3.38 [not significant decrease: p = 0.14], p = 0.0009; [treated PD patients] LD: 7.71 +/- 4.35 [significant decrease: p = 2.48 E-06] vs. A: 5.19 +/- 4.32 [significant decrease: p = 7.83 E-05], p = 0.07). We suggest diagnostic acute challenge test performance with LD as first- and A as second choice due to better tolerability and valuation in combination with repeated scoring procedures to improve sensitivity and specifity. |
| doi_str_mv | 10.1007/s00702-003-0815-y |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_217840351</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>712849491</sourcerecordid><originalsourceid>FETCH-LOGICAL-c354t-2107be209fca0589ec27d5e9eace16d05755aa47d6f2ac6dcc4252ac8d9dbf3f3</originalsourceid><addsrcrecordid>eNpFkNtKAzEQhoMoWg8P4I0EQbxanWw2e7iU4gkERfQ6TpPZmrrN1mQr9O1NaaE3mQS-fzLzMXYu4EYAVLcxHZBnADKDWqhstcdGopAqE0Up99kIJEDWqLI4YscxzgBAiKo-ZEcir8paqnLEvt5pQTiQ5QEH56fczReh_6PI_7BbEu9bbh1OfR8HZ7jtFzh3nsI0Pcw3dh35KfGB4hC58_wNw4_zsffXMcUiYaRTdtBiF-lsW0_Y58P9x_gpe3l9fB7fvWRGqmLIcgHVhHJoWoOg6oZMXllFDaEhUVpQlVKIRWXLNkdTWmOKXKVbbRs7aWUrT9jlpm8a_3eZBtKzfhl8-lLnaekCpBIJEhvIhD7GQK1eBDfHsNIC9Fqp3ijVSaleK9WrlLnYNl5O5mR3ia3DBFxtAYwGuzagNy7uuKIupWiE_Ac9SICm</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>217840351</pqid></control><display><type>article</type><title>Repeated rating improves value of diagnostic dopaminergic challenge tests in Parkinson's disease</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>MÜLLER, Th ; BENZ, S ; BÖRNKE, C ; RUSS, H ; PRZUNTEK, H</creator><creatorcontrib>MÜLLER, Th ; BENZ, S ; BÖRNKE, C ; RUSS, H ; PRZUNTEK, H</creatorcontrib><description>Clinicians use acute challenges with levodopa (LD) and/or apomorphine (A) for diagnostic dopaminergic response tests in Parkinson's disease (PD) patients. We consecutively compared the value of both drugs with performance of repeated ratings and adverse effect recording. Oral administration of 200 mg LD was superior to subcutaneous injection of 4 mg A in terms of tolerability and onset of temporary UPDRS motor score decline ([previously untreated PD patients] LD: 4.02 [mean] +/- 2.45 [SD] [significant decrease: p = 1.42 E-07] vs. A: 1.58 +/- 3.38 [not significant decrease: p = 0.14], p = 0.0009; [treated PD patients] LD: 7.71 +/- 4.35 [significant decrease: p = 2.48 E-06] vs. A: 5.19 +/- 4.32 [significant decrease: p = 7.83 E-05], p = 0.07). We suggest diagnostic acute challenge test performance with LD as first- and A as second choice due to better tolerability and valuation in combination with repeated scoring procedures to improve sensitivity and specifity.</description><identifier>ISSN: 0300-9564</identifier><identifier>EISSN: 1435-1463</identifier><identifier>DOI: 10.1007/s00702-003-0815-y</identifier><identifier>PMID: 12768356</identifier><identifier>CODEN: JNTMAH</identifier><language>eng</language><publisher>Wien: Springer</publisher><subject>Administration, Oral ; Adult ; Aged ; Apomorphine - adverse effects ; Biological and medical sciences ; Double-Blind Method ; Drug Administration Routes ; Drug Tolerance - physiology ; Female ; Fundamental and applied biological sciences. Psychology ; Humans ; Injections, Subcutaneous ; Levodopa - adverse effects ; Male ; Middle Aged ; Parkinson Disease - diagnosis ; Parkinson Disease - drug therapy ; Parkinson Disease - physiopathology ; Parkinson's disease ; Treatment Outcome</subject><ispartof>Journal of Neural Transmission, 2003-06, Vol.110 (6), p.603-609</ispartof><rights>2003 INIST-CNRS</rights><rights>Copyright Springer-Verlag 2003</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c354t-2107be209fca0589ec27d5e9eace16d05755aa47d6f2ac6dcc4252ac8d9dbf3f3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14863191$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12768356$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>MÜLLER, Th</creatorcontrib><creatorcontrib>BENZ, S</creatorcontrib><creatorcontrib>BÖRNKE, C</creatorcontrib><creatorcontrib>RUSS, H</creatorcontrib><creatorcontrib>PRZUNTEK, H</creatorcontrib><title>Repeated rating improves value of diagnostic dopaminergic challenge tests in Parkinson's disease</title><title>Journal of Neural Transmission</title><addtitle>J Neural Transm (Vienna)</addtitle><description>Clinicians use acute challenges with levodopa (LD) and/or apomorphine (A) for diagnostic dopaminergic response tests in Parkinson's disease (PD) patients. We consecutively compared the value of both drugs with performance of repeated ratings and adverse effect recording. Oral administration of 200 mg LD was superior to subcutaneous injection of 4 mg A in terms of tolerability and onset of temporary UPDRS motor score decline ([previously untreated PD patients] LD: 4.02 [mean] +/- 2.45 [SD] [significant decrease: p = 1.42 E-07] vs. A: 1.58 +/- 3.38 [not significant decrease: p = 0.14], p = 0.0009; [treated PD patients] LD: 7.71 +/- 4.35 [significant decrease: p = 2.48 E-06] vs. A: 5.19 +/- 4.32 [significant decrease: p = 7.83 E-05], p = 0.07). We suggest diagnostic acute challenge test performance with LD as first- and A as second choice due to better tolerability and valuation in combination with repeated scoring procedures to improve sensitivity and specifity.</description><subject>Administration, Oral</subject><subject>Adult</subject><subject>Aged</subject><subject>Apomorphine - adverse effects</subject><subject>Biological and medical sciences</subject><subject>Double-Blind Method</subject><subject>Drug Administration Routes</subject><subject>Drug Tolerance - physiology</subject><subject>Female</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Humans</subject><subject>Injections, Subcutaneous</subject><subject>Levodopa - adverse effects</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Parkinson Disease - diagnosis</subject><subject>Parkinson Disease - drug therapy</subject><subject>Parkinson Disease - physiopathology</subject><subject>Parkinson's disease</subject><subject>Treatment Outcome</subject><issn>0300-9564</issn><issn>1435-1463</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkNtKAzEQhoMoWg8P4I0EQbxanWw2e7iU4gkERfQ6TpPZmrrN1mQr9O1NaaE3mQS-fzLzMXYu4EYAVLcxHZBnADKDWqhstcdGopAqE0Up99kIJEDWqLI4YscxzgBAiKo-ZEcir8paqnLEvt5pQTiQ5QEH56fczReh_6PI_7BbEu9bbh1OfR8HZ7jtFzh3nsI0Pcw3dh35KfGB4hC58_wNw4_zsffXMcUiYaRTdtBiF-lsW0_Y58P9x_gpe3l9fB7fvWRGqmLIcgHVhHJoWoOg6oZMXllFDaEhUVpQlVKIRWXLNkdTWmOKXKVbbRs7aWUrT9jlpm8a_3eZBtKzfhl8-lLnaekCpBIJEhvIhD7GQK1eBDfHsNIC9Fqp3ijVSaleK9WrlLnYNl5O5mR3ia3DBFxtAYwGuzagNy7uuKIupWiE_Ac9SICm</recordid><startdate>20030601</startdate><enddate>20030601</enddate><creator>MÜLLER, Th</creator><creator>BENZ, S</creator><creator>BÖRNKE, C</creator><creator>RUSS, H</creator><creator>PRZUNTEK, H</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope></search><sort><creationdate>20030601</creationdate><title>Repeated rating improves value of diagnostic dopaminergic challenge tests in Parkinson's disease</title><author>MÜLLER, Th ; BENZ, S ; BÖRNKE, C ; RUSS, H ; PRZUNTEK, H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c354t-2107be209fca0589ec27d5e9eace16d05755aa47d6f2ac6dcc4252ac8d9dbf3f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Administration, Oral</topic><topic>Adult</topic><topic>Aged</topic><topic>Apomorphine - adverse effects</topic><topic>Biological and medical sciences</topic><topic>Double-Blind Method</topic><topic>Drug Administration Routes</topic><topic>Drug Tolerance - physiology</topic><topic>Female</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Humans</topic><topic>Injections, Subcutaneous</topic><topic>Levodopa - adverse effects</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Parkinson Disease - diagnosis</topic><topic>Parkinson Disease - drug therapy</topic><topic>Parkinson Disease - physiopathology</topic><topic>Parkinson's disease</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>MÜLLER, Th</creatorcontrib><creatorcontrib>BENZ, S</creatorcontrib><creatorcontrib>BÖRNKE, C</creatorcontrib><creatorcontrib>RUSS, H</creatorcontrib><creatorcontrib>PRZUNTEK, H</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><jtitle>Journal of Neural Transmission</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>MÜLLER, Th</au><au>BENZ, S</au><au>BÖRNKE, C</au><au>RUSS, H</au><au>PRZUNTEK, H</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Repeated rating improves value of diagnostic dopaminergic challenge tests in Parkinson's disease</atitle><jtitle>Journal of Neural Transmission</jtitle><addtitle>J Neural Transm (Vienna)</addtitle><date>2003-06-01</date><risdate>2003</risdate><volume>110</volume><issue>6</issue><spage>603</spage><epage>609</epage><pages>603-609</pages><issn>0300-9564</issn><eissn>1435-1463</eissn><coden>JNTMAH</coden><abstract>Clinicians use acute challenges with levodopa (LD) and/or apomorphine (A) for diagnostic dopaminergic response tests in Parkinson's disease (PD) patients. We consecutively compared the value of both drugs with performance of repeated ratings and adverse effect recording. Oral administration of 200 mg LD was superior to subcutaneous injection of 4 mg A in terms of tolerability and onset of temporary UPDRS motor score decline ([previously untreated PD patients] LD: 4.02 [mean] +/- 2.45 [SD] [significant decrease: p = 1.42 E-07] vs. A: 1.58 +/- 3.38 [not significant decrease: p = 0.14], p = 0.0009; [treated PD patients] LD: 7.71 +/- 4.35 [significant decrease: p = 2.48 E-06] vs. A: 5.19 +/- 4.32 [significant decrease: p = 7.83 E-05], p = 0.07). We suggest diagnostic acute challenge test performance with LD as first- and A as second choice due to better tolerability and valuation in combination with repeated scoring procedures to improve sensitivity and specifity.</abstract><cop>Wien</cop><cop>New York, NY</cop><pub>Springer</pub><pmid>12768356</pmid><doi>10.1007/s00702-003-0815-y</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0300-9564 |
| ispartof | Journal of Neural Transmission, 2003-06, Vol.110 (6), p.603-609 |
| issn | 0300-9564 1435-1463 |
| language | eng |
| recordid | cdi_proquest_journals_217840351 |
| source | MEDLINE; SpringerNature Journals |
| subjects | Administration, Oral Adult Aged Apomorphine - adverse effects Biological and medical sciences Double-Blind Method Drug Administration Routes Drug Tolerance - physiology Female Fundamental and applied biological sciences. Psychology Humans Injections, Subcutaneous Levodopa - adverse effects Male Middle Aged Parkinson Disease - diagnosis Parkinson Disease - drug therapy Parkinson Disease - physiopathology Parkinson's disease Treatment Outcome |
| title | Repeated rating improves value of diagnostic dopaminergic challenge tests in Parkinson's disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T10%3A41%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Repeated%20rating%20improves%20value%20of%20diagnostic%20dopaminergic%20challenge%20tests%20in%20Parkinson's%20disease&rft.jtitle=Journal%20of%20Neural%20Transmission&rft.au=M%C3%9CLLER,%20Th&rft.date=2003-06-01&rft.volume=110&rft.issue=6&rft.spage=603&rft.epage=609&rft.pages=603-609&rft.issn=0300-9564&rft.eissn=1435-1463&rft.coden=JNTMAH&rft_id=info:doi/10.1007/s00702-003-0815-y&rft_dat=%3Cproquest_cross%3E712849491%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=217840351&rft_id=info:pmid/12768356&rfr_iscdi=true |